![Neurothera Labs logo](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 20 20"><rect fill="%23e5e7eb" width="20" height="20" rx="4"/></svg>)
September 2026
Largest BioTech Public Companies in Canada
Benchmark revenue and EBITDA valuation multiples for public comps like
Celestica, Bausch + Lomb, Xenon Pharmaceuticals, Apotex Health and AbCellera.
 | Celestica Inc offers supply chain solutions. The company has two operating and reportable segments: Advanced Technology Solutions (ATS) and Connectivity & Cloud Solutions (CCS). The ATS segment consists of the ATS end market and is comprised of the Aerospace and Defense, Industrial, health tech, and Capital Equipment businesses. Its Capital Equipment business is comprised of the semiconductor, display, and robotics equipment businesses, and the CCS segment consists of Communications and Enterprise end markets, The Enterprise end market is comprised of its servers and storage businesses. The company generates a majority of its revenue from the Connectivity & Cloud Solutions segment. | $300 | +22% | $38B | $38B | 3.1x | 31.4x | ||
| Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space. | $17 | +15% | $6.2B | $11B | 2.2x | 21.7x | ||
| Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain. | $60 | +50% | $5.8B | $4.9B | 654.3x | (13.3x) | ||
| Apotex Health Corp is a Canadian-based health company with a broad portfolio of generic, biosimilar and branded pharmaceuticals, as well as branded consumer health and wellness products. Its business lines include Conventional Generics, Specialty Generics and Brands & Biosimilars. The maximum revenue is derived from the Conventional Generics business, which are off-patent, small molecule oral solid dose pharmaceuticals that are bioequivalent to branded pharmaceuticals. It has three geographic operating segments: (i) Canada; (ii) the U.S.; and (iii) International. The majority of revenue is derived from Canada. | $23 | -- | $5.3B | $7.3B | 2.9x | 11.2x | ||
| AbCellera Biologics Inc is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company’s experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program. | $12 | +129% | $3.7B | $3.3B | 44.2x | (18.8x) | ||
| Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment. | $6 | -2% | $2.4B | $23B | 2.2x | 7.3x | ||
| Jamieson Wellness Inc is engaged in the manufacturing, development, distributing, and marketing of branded natural health products, including vitamins, minerals, and supplements. The company operates in two segments: The Jamieson brands and The Strategic Partners. The majority of its revenue comes from the Jamieson brand segment. Some of its brands are Jamieson, Youtheory, Progressive, Precision, Smart Solutions, and Iron Vegan. Geographically, the majority of its revenue is derived from the domestic market. | $33 | +27% | $1.4B | $1.7B | 2.9x | 17.9x | ||
| Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets . The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically the company generates revenue from Brazil, Colombia, Argentina, Rest of LATAM, Canada, and Other, with the majority revenue generated from the Brazil region. | $7 | +65% | $684M | $621M | 1.9x | 15.9x | ||
| enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. | -- | -- | $572M | $330M | - | - | ||
| Verano Holdings Corp is a vertically integrated multi-state cannabis operator in the United States. The Company has two reportable segments: (i) cultivation (wholesale) and (ii) retail. The company's consumer brands include Encore, Avexia, MUV, Savvy, BITS and Verano. The company's retail dispensaries operate under brands including Zen Leaf and MUV. The company derives its revenues from Retail segment. | $6 | -10% | $450M | $866M | 1.1x | 36.8x | ||
| Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. | $6 | +10% | $427M | $321M | - | (8.4x) | ||
| Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner. | $7 | +40% | $249M | $217M | 13.5x | (5.1x) | ||
| NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300. | $2 | -5% | $240M | $179M | - | (9.9x) | ||
| Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure. | $2 | +93% | $231M | $213M | - | (8.6x) | ||
| Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease, for which there are limited or no treatment options. The Company’s current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company’s commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations. | $9 | +41% | $200M | $159M | 15.5x | (7.1x) | ||
| Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease. | $9 | +62% | $199M | $136M | ||||
| Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR). | $1 | -42% | $144M | $34M | ||||
| ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. | $13 | +29% | $118M | $64M | ||||
| Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others. | $1 | -39% | $107M | $103M | ||||
| Cizzle Brands Corp is engaged in health & wellness industry. It focuses to replace all of the unhealthy, sugary and fattening foods filling cupboards with healthy, nutritious alternatives. Its product CWENCH and Spoken Nutrition. Its two operating are the retail/wholesale segment; and three location segments are: Canada, the United States and Others. | $0 | -- | $57M | $135M | ||||
| Neurothera Labs Inc is a specialty clinical-stage pharmaceutical company. The company's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. With this focus, it has been engaged in developing and testing pharmaceutical compositions comprised of N-acylethanolamines and cannabinoids such as PEA, delta-9THC and CBD and/or other cannabinoid receptors agonists. | $0 | -- | $42M | $42M | ||||
| NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications. | $0 | -- | $36M | $35M | ||||
| Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL-13 Superkines and Empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. Its pipeline candidates include MDNA11 for Cancer immunotherapies, MDNA55 is a Molecular Trojan Horse, and BiSKITs represent a novel platform comprised of Bifunctional SuperKine ImmunoTherapies. | $0 | -52% | $31M | $27M | ||||
| LSL Pharma Group Inc integrated pharmaceutical company specializing in the development, manufacture and distribution of high-quality natural health products and dietary supplements in solid dosage forms as well as high quality sterile ophthalmic pharmaceutical products. | $0 | -8% | $31M | $66M | ||||
| ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union. | $0 | -- | $29M | $44M | ||||
| Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). It is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and various biomedical applications. The company's product includes Gemini and Saliva tests. | $0 | -- | $28M | $29M | ||||
| Optimi Health Corp operates in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector. The company has one reportable operating segment being that of the farming, processing, and distribution of raw mushroom biomass. It also intends to cultivate, extract, process, and distribute strains of fungi products at its facilities located in Princeton, British Columbia. | $5 | -- | $28M | $22M | ||||
| Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property. | $3 | -80% | $26M | $21M | ||||
| Cheelcare Inc is a company that designs and manufactures inventive mobility devices using robotics. Its product portfolio consists of three key lines: Robotic Complex Rehab Power Wheelchair such devices feature patented self-leveling technology and the lowest seat-to-floor height in their class, enhancing stability and accessibility. Power Add-ons for Manual Wheelchairs designed to convert manual wheelchairs into powered mobility devices, offering users increased independence. Aftermarket Wheelchair Accessories includes a range of OEM equipment, backup cameras, phone chargers, and wheel suspension systems, that allow wheelchair users the ability to supplement their existing equipment to improve safety and convenience. | $1 | -- | $23M | $23M | ||||
| Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology. | $11 | -21% | $19M | $15M | ||||
| Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy. | $0 | -- | $17M | $23M | ||||
| Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product. | $4 | -43% | $17M | $9M | ||||
| Conavi Medical Corp is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its Novasight Hybrid System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. | $0 | -- | $16M | $26M | ||||
| Avicanna Inc is a commercial-stage international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for the medical and pharmaceutical market segments. It has three operating segments: Canada, International, and Corporate. It generates the majority of its revenue from Canada. | $0 | -- | $13M | $19M | ||||
| InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company’s operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer’s disease. | $1 | -20% | $7M | $2M | ||||
| Abattis Bioceuticals Corp is a Canadian life science and biotechnology company focuses on aggregating, integrating and investing in agricultural technologies and biotechnology services for the legal cannabis industry. It is primarily engaged in producing, licensing and marketing proprietary ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The company is also engaged in growing, extraction, testing, propagation and online distribution. | -- | -- | $5M | $5M | ||||
| Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel. | $2 | -- | $3M | ($11M) | ||||
| Sunniva Inc is vertically integrated medical cannabis company committed to delivering safe, low-cost, high-quality products and services at scale. The company is focused on the cultivation, production and distribution of therapeutic solutions targeting two of the medical cannabis markets in the world: Canada and California. | Cannabis+1 | $0 | -- | $1M | $46M | |||
| Aion Therapeutic Inc is in the business of research and development, treatment, data mining, and state of the art artificial intelligence techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals, and cosmeceuticals utilizing compounds from cannabis, psychedelic mushrooms, fungi, natural psychedelic formulations, and other medicinal plants in a legal environment for this type of discovery. During the year ended the Company had one operating segment, being health and wellness, dedicated to delivering state-of-the-art water filtration solutions. Geographically company earns revenue from USA. | Cannabis+1 | $0 | +18% | $994K | $994K | |||
| Pharmadrug Inc is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and naturally derived approved drugs. The Company’s operations comprise of the corporate division in Canada. Geographically, it operates in Germany and Canada. | $0 | -50% | $483K | $1M | ||||
| RAMM Pharma Corp is engaged in the pharmaceutical and medical product business, including cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other cannabis-based products. The group generates revenue from the sale of medical devices and consumables, the sale of pharmaceutical products, and sale of cosmetics. Geographically, it derives a majority of its revenue from Uruguay. | Cannabis+1 | $0 | -50% | $430K | $376K | |||
| MYND Life Sciences Inc is a medical biotech drug research and development company. The company is focused on neuro pharmaceutical and novel drug development, diagnostics, and vaccines and is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by different molecular concepts for the applications of psilocybin analogs for overcoming diseases. | $0 | -- | $387K | $5M | ||||
| Modern Plant Based Foods Inc is a Canadian food company engaged in developing and selling plant-based meat alternatives made from plants. It offers a portfolio of plant-based products including meat alternatives, dairy-free cheeses, homemade style soups and vegan snacks. The company's product lineup includes the modern burgers, modern crabcakes, modern meatballs, modern crumbles, and sauces. It offers its products through various retail locations in the British Columbia Lower Mainland, as well as on e-commerce platforms. The company's revenue consists of sales of plant-based and health food products to wholesale and retail customers. Geographically, it derives the maximum revenue from Canada. | $0 | -83% | $180K | $2M | ||||
| PlantFuel Life Inc is focused on delivering PLANT FUELED nutritional supplements to consumers. It utilizes a multi-approach: a process including formulations using clinically proved, banned substance-free ingredients that do not compromise on flavor, digestion quality, or performance output. | $0 | -- | $180K | $2M | ||||
| Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products namely Tacrolimus IR and Vistitan. | $0 | -- | $159K | $5M | ||||
| MyndTec Inc is a medical technology company. It researches, develops, and distributes new therapies designed to improve function, maximize independence and enhance the quality of life for individuals with upper limb paralysis due to stroke, spinal cord injury, or traumatic brain injury. The firm develops non-invasive neurological and nervous system electrical stimulation therapeutics for the treatment of neurological diseases and injuries specifically targeted to markets with large, growing, and patient populations. The company generates revenues from sales in Canada and the United States. | $0 | -- | $115K | $359K | ||||
| Transnational Cannabis Ltd, formerly ICC International Cannabis Corp is a Canadian company which is engaged in planning, designing, building and operating cannabis production, processing, and distribution facilities. The company through its holdings is engaged in the pharmaceutical distribution, wholesale importation, research, and development, as well as working interests in industrial hemp licenses in Greece, licenses to cultivate, produce, distribute, store, and export Cannabis and Cannabis derivatives in Colombia, the Kingdom of Lesotho, Africa, and Denmark. | Cannabis+1 | $0 | -- | $74K | $74K | |||
| Easton Pharmaceuticals Inc is a diversified specialty pharmaceutical company. It owns and develops proprietary transdermal delivery technology and therapeutic over the counter products and drugs to treat cancer and other diseases. The company also owns exclusive distribution rights in Mexico and Latin America for patented women's diagnostic and preventative care products. It is focused on the development of product Viorra. The firm's products include Nauseasol, Skin Renou HA, Kenestrin gel, and XILIVE, among others. | $0 | -- | $27K | $27K | ||||
| Filament Health Corp is a natural psychedelic drug development company. Its mission is to see safe, approved, natural psychedelics in the hands of everyone who needs them as soon as possible. The group engages in natural extraction technology commercialization, utilizing its intellectual property portfolio, in-house GMP facility, and Health Canada psilocybin Dealer's License. | -- | -- | $26K | $96K | ||||
| Isodiol International Inc is a manufacturer and developer of phytoceutical consumer products using pharmaceutical and nutraceutical grade phytochemical compounds. It generates revenue from the sale of nutritional health products derived from hemp. Geographically, it derives a majority of revenue from the United States and also has a presence in Canada. Its product categories include Tinctures; Capsules; Topicals; Vape; Oral Spray; Skincare; and others. | -- | -- | $5K | $5K | ||||
| Nextraction Energy Corp has currently no operations. | Cannabis+1 | $0 | -- | $4K | $6M | |||
| Median | $1 | -2% | $28M | $29M | 4.0x | (2.3x) |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.